Recombinant multi-species TCF7L1/TCF7L2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TCF7L1/TCF7L2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the T cell factor/lymphoid enhancer factor family of transcription factors. These transcription factors are activated by beta catenin, mediate the Wnt signaling pathway and are antagonized by the transforming growth factor beta signaling pathway. The encoded protein contains a high mobility group-box DNA binding domain and participates in the regulation of cell cycle genes and cellular senescence. [provided by RefSeq, Nov 2010]
The Alternative Names of target: HMG box transcription factor 3 (TCF-3),TCF-3,TCF3,TCF7L1,TCF7L2,Tcf-3,Tcf3,Tcf7l1,Transcription factor 7-like 1,bHLHb21
Go
to TCF7L1/TCF7L2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP12654-Ag-1/ GM-Tg-hg-IP12654-Ag-2 | Human TCF7L1/TCF7L2 protein | Human |
| GM-Tg-rg-IP12654-Ag-1/ GM-Tg-rg-IP12654-Ag-2 | Rat TCF7L1/TCF7L2 protein | Rat |
| GM-Tg-mg-IP12654-Ag-1/ GM-Tg-mg-IP12654-Ag-2 | Mouse TCF7L1/TCF7L2 protein | Mouse |
| GM-Tg-cynog-IP12654-Ag-1/ GM-Tg-cynog-IP12654-Ag-2 | Cynomolgus/Rhesus macaque TCF7L1/TCF7L2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP12654-Ag-1/ GM-Tg-felg-IP12654-Ag-2 | Feline TCF7L1/TCF7L2 protein | Feline |
| GM-Tg-cang-IP12654-Ag-1/ GM-Tg-cang-IP12654-Ag-2 | Canine TCF7L1/TCF7L2 protein | Canine |
| GM-Tg-bovg-IP12654-Ag-1/ GM-Tg-bovg-IP12654-Ag-2 | Bovine TCF7L1/TCF7L2 protein | Bovine |
| GM-Tg-equg-IP12654-Ag-1/ GM-Tg-equg-IP12654-Ag-2 | Equine TCF7L1/TCF7L2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP12654-Ag-1/ GM-Tg-hg-IP12654-Ag-2;
GM-Tg-rg-IP12654-Ag-1/ GM-Tg-rg-IP12654-Ag-2;
GM-Tg-mg-IP12654-Ag-1/ GM-Tg-mg-IP12654-Ag-2; GM-Tg-cynog-IP12654-Ag-1/ GM-Tg-cynog-IP12654-Ag-2; GM-Tg-felg-IP12654-Ag-1/ GM-Tg-felg-IP12654-Ag-2; GM-Tg-cang-IP12654-Ag-1/ GM-Tg-cang-IP12654-Ag-2; GM-Tg-bovg-IP12654-Ag-1/ GM-Tg-bovg-IP12654-Ag-2; GM-Tg-equg-IP12654-Ag-1/ GM-Tg-equg-IP12654-Ag-2 |
| Products Name | TCF7L1/TCF7L2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | TCF7L1/TCF7L2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TCF7L1/TCF7L2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.